A significant role of epigenetic modifications in the development of hypertension is strongly supported by numerous studies. However, studies of epigenetic modifications in hypertension at the genome or near-genome scale are just beginning to emerge. The epigenomics of hypertension remains a large, open field, and with recent advances in technology, it is a field that is ripe for paradigm-shifting discoveries in hypertension research. We propose to establish a Center focusing on investigating the epigenomics of hypertension. The overall hypothesis is that dietary salt intake and other lifestyle factors, maternal dietary exposures, and gene-environment interactions cause genome-wide changes in DNA methylation in immune cells, which contribute to the development of hypertension and can be used as predictive or diagnostic markers of hypertension and related diseases. This overall hypothesis will be tested in three highly integrated projects:Project 1: David L. Mattson, PhD. Epigenetic Modification of Immune Mechanisms in Salt-Sensitive Hypertension and Renal DamageProject 2: Srividya Kidambi, MD, Epigenomics of Hypertension in Monozygotic Twins and Effect of Salt IntakeProject 3: Theodore A. Kotchen, MD, Epigenomic Modifications in Hypertension and Hypertension-Related Cardiovascular DiseasesThe proposed Center will offer several unique values and strengths. It will explore a broad, novel area of hypertension research, which could drive hypertension research to advance in new directions in the next decade and beyond. It will build on substantial expertise in diverse disciplines and cutting-edge technologies available in a group of key investigators at a single location (MCW) with a long history of successful collaboration in hypertension research.
|Program type||Strategically Focused Research Network|
|Effective start/end date||04/01/2015 → 03/31/2019|